Effect of Kinesio Taping on Pain, Posture and Function in Lower Cross Syndrome

October 23, 2024 updated by: Riphah International University

Effect of Kinesio Taping on Pain, Posture and Function in Patient With Lower Cross Syndrome

Determine the impact of Kinesio taping on pain, postural alignment and functional outcomes in individuals with lower cross syndrome.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Participants with lower cross syndrome who present to physical therapy department will be screened for eligibility on basis of inclusion and exclusion criteria. Group A will receive the treatment with moist hot pack along with stretching of tight erector spinae, hip flexors and strengthening of weak abdominals and gluteal muscles along with Kinesiotaping using inhibition and facilitation technique for LCS and Group B will receive the treatment with moist hot pack along with stretching of tight erector spinae, hip flexors and strengthening of weak abdominals and gluteal muscles. The patients will receive the treatment sessions 3 days per week for almost 04 weeks. They will be evaluated after the treatment for PAIN, POSTURAL ASSESSMENT, FUNCTIONAL DISABILITY in order to check for the effect of the treatment.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
44

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • Punjab
      • Rawalpindi, Punjab, Pakistan, 46060
        • Railway hospital Rawalpindi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age- 30 to 50 years.
  • Female patients.
  • Anterior pelvic tilting > 7-10 degrees.
  • Postural imbalance characterized by anterior pelvic tilt, lumbar hyper lordosis, and associated muscle imbalances.
  • Discomfort, pain, or limitations related to the lower back, pelvis, and hips attributed to LCS.
  • Willing to provide informed consent to participate in the study.

Exclusion Criteria:

  • Musculoskeletal pathologies affecting the lower back, pelvis, hips, or lower extremities (e.g., herniated disc, lumbar radiculopathy, lumbar stenosis, hip labral tear).
  • Kinesiotaping interventions for LCS in the past 3 months.
  • Allergies to tape materials or skin sensitivities that might prevent safe tape application.
  • Pregnant individuals due to potential discomfort.
  • Open wounds, infections, or skin conditions at the taping application site.
  • Severe cardiovascular, pulmonary, renal, or neurological diseases.
  • In other clinical trials involving interventions for LCS.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Kinesio taping along with conventional physical therapy
treatment with moist hot pack along with stretching of tight erector spinae, hip flexors and strengthening of weak abdominals and gluteal muscles along with Kinesiotaping using inhibition and facilitation technique for LCS.
Other: Kinesio taping

Kinesiotaping using inhibition technique in tight muscles and facilitation technique in weak muscles for LCS. Treatment sessions 3 days per week for almost 04 weeks.

10 mins moist hot pack

  • Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.
  • Strengthening of weak abdominals and gluteal muscles 2-3 times in a week
Other: Conventional physical therapy

10 mins moist hot pack

  • Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.
  • Strengthening of weak abdominals and gluteal muscles 2-3 times in a week
Active Comparator: conventional physical therapy
Treatment with moist hot pack along with stretching of tight erector spinae, hip flexors and strengthening of weak abdominals and gluteal muscles.
Other: Conventional physical therapy

10 mins moist hot pack

  • Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.
  • Strengthening of weak abdominals and gluteal muscles 2-3 times in a week

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Visual analog scale (VAS)
Time Frame: 4th week
To assess pain using a Visual Analog Scale (VAS), provide patient with a straight line ranging from "No Pain "to "Worst pain Imaginable "Ask patient to mark a point on line that represents their current pain intensity, with understanding that the left end means no pain, and the right end means the most severe pain imaginable, measure distance in millimeters from "No pain "end to the marked point to quantify the pain level. Pain is assess at the end of every week.
4th week
Anterior pelvic tilting
Time Frame: 4th week
The hand-held pelvic inclinometer's is use for measure anterior pelvic tilting. Anterior pelvic tilting is measure at the end of every week.
4th week
Oswestry Disability Index (ODI)
Time Frame: 4th week
The Oswestry Disability Index (ODI) is a widely used questionnaire to assess the functional disability and impact of lower back pain on an individual's daily life. Patients are asked to rate their level of disability on a scale from 0 to 5, with 0 indicating no disability and 5 indicating the highest level of disability. It is divided into ten sections that each target various tasks or functions. Higher percentages indicate greater disability. Functional disability through ODI assess after every 2nd week.
4th week
Muscle Length
Time Frame: 4th week
The length of the bilateral Iliopsoas muscle was measured using a Universal Goniometer and the Modified Thomas test. A non-elastic measuring tape was used to examine the length of the spinal extensor muscle. Abdominal muscular strength and bilateral Gluteus maximus Manual muscle testing was graded according to the MRC grading system.
4th week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Asmar Fatima, MS OMPT, Riphah International University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 13, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 31, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 30, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 4, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 4, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 12, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 26, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 23, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/MS-PT/01718 Nida Kausar

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings